In advanced, progressive, well-differentiated nonfunctional GI and lung NET
The RADIANT-4 population had a diverse range of patient characteristics1
Prognostic subgroups used in stratification
- 80% of patients had received other prior anticancer treatment, including radiotherapy (21%), surgery (63%), locoregional therapy (11%), and antineoplastic medications (31%)3
Select demographic characteristics
CUP, cancer of unknown primary; GI, gastrointestinal; NET, neuroendocrine tumor(s); PS, performance status; RADIANT, RAD001 in Advanced Neuroendocrine Tumors; SEER, Surveillance, Epidemiology, and End Results; SSA, somatostatin analogue; WHO, World Health Organization.
- Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968-977.
- Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072.
- Data on file. Novartis Pharma AG.